The global monoclonal antibody market is estimated to be USD 104.6 billion in 2021 and is expected to witness a CAGR of 6.81% during the forecast period. Increasing incidences of chronic diseases such as cancer, thyroid, cardiovascular diseases, technological advancements, and growing awareness levels related to early diagnoses of diseases are the factors driving the market. However, high cost of therapeutic mAbs that are used in treatment of various diseases is hindering the market growth.

By Type

On the basis of type, the global market is segmented into chimeric, murine, humanized, and human type. The market was dominated by humanized type of mAbs in 2021. The major reason for this share is increase in adoption of this type in the treatment of various diseases including cancer, inflammatory, and autoimmune diseases. The other major reason for this market growth is advancement in genetic engineering technology employed in its production is driving the market.

By Production

On the basis of the production, the market is divided into in vitro and in vivo. Both production techniques are majorly accepted and used widely on commercial level. In vivo technology is lucrative as compared to in vitro production techniques and is favoured for the high concentration of mAbs obtained through this method.

By Indication

On the basis of indication, the market is categorized into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, and others. Cancer segment accounted for the largest revenue share in the global market in 2021. Monoclonal antibody finds wide applications areas in cancer treatment. Moreover, the increasing incidence of cancer is the key contributing factor for the growth of the mAbs vertical as these treatments have been the best alternative available in comparison to the drugs and chemotherapy with minimum averse affects.

By End User

On the basis of end user, the market is segmented into hospitals, research institutes, and others. Hospital segment accounted for the largest revenue share in the global market in 2021. Increase in cases of chronic conditions increasing treatment rate, growing healthcare expenditure level, and rise in awareness level amongst the patients regarding treatment alternatives are factors supporting the dominance of hospitals segment. Research institutes segment is expected to grow at a lucrative CAGR during the forecast period.

Regional Insights

The regional market for monoclonal antibody is segmented into five regions including North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominated the global market in 2021. Well established healthcare infrastructure and continuous investment from the government for technological development are driving the market in this region. Asia Pacific market is the most profitable market, because of presence of a large number of future growth opportunities in the region. The region displayed the highest CAGR during the forecast period. Unmet needs coupled with the growth in the healthcare infrastructure is expected to boost the growth over the forecast period.

Competitor Insights

Some of the major companies in the market Novartis AG (Switzerland), Pfizer Inc (U.S.), GlaxoSmithKline plc (U.K.), Amgen Inc. (U.S.), Merck & Co. Inc (U.S.), Daiichi Sankyo Company Ltd. (Japan), Abbott Laboratories (U.S.), AstraZeneca (U.K.), Eli Lilly (U.S.), Johnson & Johnson Services Inc. (U.S.), Bayer AG (Germany), Bristol Myers Squibb Co. (U.S.), Mylan N.V. (U.S.), Biogen Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.). Investment in R&D, strategic collaborations & acquisitions, and novel product launches are some of the major strategies adopted by the leading players operating in the industry.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The monoclonal antibody market report is categorized into the following segments and subsegments:

Monoclonal Antibody Market, By Type (Revenue, 2021-2029, USD Billion)

• Murine
• Chimeric
• Humanized
• Human

Monoclonal Antibody Market, By Production (Revenue, 2021-2029, USD Billion)

• In vitro
• In vivo

Monoclonal Antibody Market, By Indication (Revenue, 2021-2029, USD Billion)

• Cancer
• Autoimmune diseases
• Inflammatory diseases
• Infectious diseases
• Microbial diseases
• Others

Monoclonal Antibody Market, By End User (Revenue, 2021-2029, USD Billion)

• Hospitals
• Research Institutes
• Others

Monoclonal Antibody Market, By Region (Revenue, 2021-2029, USD Billion)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA

Scope of Monoclonal Antibody Market Report:

Key Parameters	Details
Base Year	2021
Forecast Period	2022-2029
Study Coverage	Global and regional market size and revenue forecast Segment market size and revenue forecast at global, regional, and country level Competitive landscape (company share analysis, company profiles, recent development, competitive map analysis) Conclusion and recommendations
Qualitative Analysis	Market drivers Market restraints Market opportunities Recent market trends Market challenges Porter’s Five Forces analysis PEST analysis Value-chain analysis COVID-19 impact analysis
Regional Market Scope	North America (U.S. and Canada) Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe) Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC) Latin America (Brazil, Mexico, Argentina, Rest of LATAM) MEA (South Africa, GCC, Rest of MEA)
Company Profiles	Exhaustive profiles of top 15 players 50+ other major players listing
15% Free Customization Available	You can customize the study scope to meet your exact requirement. Click here for more details